PPD

Hill steps down as CEO following closing of PPD acquisition

Thursday, December 15, 2011 02:45 PM

Raymond Hill has stepped down as CEO of PPD, less than three months after taking the top post at the U.S.-based global CRO, according to a report from PharmaTimes. The announcement followed last week’s completion of PPD’s acquisition by affiliates of global investment firms The Carlyle Group and Hellman & Friedman and the company officially being taken private.

More... »

Survey: Sponsor’s choice of central lab affects investigator’s satisfaction with trial experience

Monday, December 12, 2011 09:04 AM

The choice of a central lab can greatly affect a principal investigator’s satisfaction level while conducting a clinical trial. 

More... »

PPD shareholders approve merger with The Carlyle Group, Hellman & Friedman

Thursday, December 1, 2011 11:06 AM

PPD has reported that its shareholders have voted to approve the adoption of the agreement and plan of merger, providing for the merger of the company with an entity controlled by affiliates of The Carlyle Group and affiliates of Hellman & Friedman.

More... »

CRO top executives in a game of ‘musical chairs’

Monday, November 7, 2011 08:02 AM

Five months after INC Research’s acquisition of Kendle International closed, executives from the now-combined CRO are landing jobs with competitors.  

More... »

Scrip names PPD best CRO

Friday, November 4, 2011 11:43 AM

More... »

Potthoff named president, CEO of Theorem Clinical Research

Wednesday, November 2, 2011 01:13 PM

John Potthoff has stepped down as chief operating officer of CRO INC Research to become president and CEO of Theorem Clinical Research, succeeding James Pusey, who now becomes Theorem’s executive chairman to the board of directors.

More... »

Survey: Top CROs doubled workforce over past decade

Monday, October 24, 2011 08:02 AM

Over the last 10 years, the top nine global CROs have more than doubled their workforce, which now exceeds 72,000 employees, and their revenues have increased at a compound annualized rate of 11% as they increasingly play a larger and more integral role in the drug development infrastructure, according to a new Association of Clinical Research Organizations (ACRO) member survey.

More... »

Carlyle Partners, Hellman & Friedman to acquire PPD for $3.9 billion, take the CRO private

Monday, October 10, 2011 08:02 AM

It’s official: Large equity investors Carlyle Partners and Hellman & Friedman Capital Partners are buying publicly traded PPD, taking the CRO private.

More... »

The Carlyle Group, Hellman & Friedman to acquire PPD

Tuesday, October 4, 2011 10:42 AM

Pharmaceutical Product Development (PPD) has entered into a definitive merger agreement under which it will be acquired by affiliates of The Carlyle Group and Hellman & Friedman in an all-cash transaction valued at $3.9 billion, after which PPD will be a private company.

More... »

New technology earns Quintiles top 5 ranking

Monday, October 3, 2011 08:00 AM

Many companies brag about bringing innovative technology to the clinical trials industry. Quintiles doesn’t have to brag. The most recent InformationWeek 500 is doing that for it.

More... »